Moderna Backs Off COVID Vaccine Patent In Dispute With NIH

By Ryan Davis (December 19, 2021, 5:26 PM EST) -- Moderna announced on Friday that it has delayed pursuing a patent on its COVID-19 vaccine while it disputes the National Institutes of Health's contention that the agency's scientists should be added as co-inventors, which could give the government greater control over the vaccine.

The pharmaceutical company said in a statement that it "has decided at this time not to pursue issuance of the U.S. patent application for the mRNA sequence of the Moderna COVID-19 vaccine that had been allowed by the U.S. Patent and Trademark Office earlier this year."

The company said it made the move "to allow more time for...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!